UAE-based pharmaceutical manufacturer Julphar has announced the launch of two medications prescribed for the management of Type 2 diabetes, Xelevia and Velmetia, as disease rates hit record levels in the Middle East.
The launch is part of Julphar’s licence, supply and co-marketing agreement signed in April 2014 with the global pharmaceutical firm Merck Sharp & Dohme, it said in a statement.
Dr Hosam Badr, marketing director at Julphar, said: "The launch of Xelevia and Velmetia is part of our continuing mission to develop Julphar diabetes portfolio, to support healthcare community in the region."
The launch comes just weeks after it was reported that diabetes rates in the Middle East have reached a record high of about 43 million cases, accounting for almost 14 percent of its adults – the highest level in the world.
Type 2 diabetes rates have especially risen due to obesity, lack of physical activity and unhealthy diets, according to the World Health Organisation. It has also been increasingly seen in children.
The chronic disease develops when the pancreas fails to produce sufficient insult to regular blood pressure. It could result in heart attacks, strokes, kidney failure, lower limb amputations or eye diseases that could cause blindness.
Subscribe to Arabian Business' newsletter to receive the latest breaking news and business stories in Dubai,the UAE and the GCC straight to your inbox.